Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Treatment of Nail Psoriasis: Diagnosis, Algorithms, and Emerging Therapies
Description
Nail psoriasis is common in patients with psoriasis and strongly associated with psoriatic arthritis, but it can be difficult to diagnose when it occurs in isolation and is often mistaken for fungal disease. A practical treatment algorithm divides disease into few nails affected (three or fewer) versus more extensive involvement. For limited disease, first-line therapy is intralesional triamcinolone (Kenalog), and for nail bed psoriasis, clipping the onycholytic nail plus a potent topical steroid with or without vitamin D is recommended; patients with more than three nails involved or with cutaneous psoriasis/psoriatic arthritis should generally receive systemic therapy. Evidence suggests low-dose intralesional injections can be effective with fewer adverse effects, and injections into the proximal nail fold may help both matrix and bed disease. Systemic options such as apremilast and newer biologics/JAK-STAT or TYK2-targeted agents show meaningful improvements, with several studies suggesting strong responses from IL-17 inhibitors and agents like ixekizumab, though comparisons are limited by study differences. Improvement is slow, often requiring six months or longer, so patient expectations are important. Quality of life is significantly affected, and smoking cessation is the main modifiable risk factor highlighted.
View moreConclusions
- Nail psoriasis should be recognized as a common and quality-of-life–impacting manifestation of psoriasis, often associated with psoriatic arthritis and sometimes present with minimal skin disease.
- For patients with three or fewer affected nails, intralesional triamcinolone remains a first-line option, especially for nail matrix disease.
- Lower intralesional steroid doses appear to work as well as higher doses while causing fewer adverse effects, making lower-dose regimens preferable.
- A single proximal nail fold injection may improve both nail matrix and nail bed disease, suggesting diffusion can treat more than one nail compartment.
- For patients with more extensive nail disease or relevant comorbid skin/joint involvement, systemic or biologic therapy should be considered.
- Apremilast can improve nail psoriasis and quality of life and appears to be well tolerated, but it should be avoided in severe lactose intolerance.
- Newer targeted therapies, especially IL-17, IL-23, JAK, and TYK2-pathway agents, can produce substantial nail improvement, with some therapies showing particularly strong responses.
- Different biologics may have differing strengths for nail matrix versus nail bed disease, so treatment selection may be individualized by nail subtype.
- Nail psoriasis improves slowly, so treatment success should be assessed over months rather than weeks and patients should be counseled to expect delayed responses.
- Smoking is a modifiable risk factor associated with worse nail psoriasis, so smoking cessation should be part of management recommendations.
- Rigopoulis D et al. J Am Acad Dermatol. 2019 Jul;81(1):228-240.
- Ricardo JW, Qiu Y, Lipner SR. Arch Dermatol Res. 2024 Mar 25;316(4):113.
- Iorizzo M, Damiani G, Lipner SR, Pacifico A, Rigopoulos D, Sechi A, Villani A, Zaraa I, Richert B. Ann Dermatol Venereol. 2025 Jun;152(2):103377.
- Yan X, et al. Front Immunol. 2025 Apr 8;16:1573715.
- Hwang JK, Ricardo JW, Lipner SR. Am J Clin Dermatol. 2023 Sep;24(5):695-720.
- Yang X, et al. Front Med (Lausanne). 2025 Dec 9;12:1660724.